Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Amazon Settles FTC Claims Ring Doorbell Spied on Users
LinkedIn becomes latest tech company to conduct layoffs
Duke and Duchess of Sussex call for overhaul of social media
Thirty Thousand Amazon Workers Could Access Alexa Data, FTC Says
China intensifies flood rescue efforts south of Beijing after historic rains
Scathing Report Targets Investment Bankers’ Emissions Math
Western Digital to Separate Flash-Memory Business. The Stock Is Rising.
Amazon to start dropping packages into people’s gardens using drones in the UK